Federated Hermes Inc. Raises Position in Corteva, Inc. $CTVA

Federated Hermes Inc. raised its stake in shares of Corteva, Inc. (NYSE:CTVA) by 333.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,530 shares of the company’s stock after acquiring an additional 15,024 shares during the period. Federated Hermes Inc.’s holdings in Corteva were worth $1,321,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Gladwyn Financial Advisors Inc. purchased a new position in Corteva in the second quarter valued at approximately $25,000. True Wealth Design LLC grew its stake in Corteva by 209.5% in the 3rd quarter. True Wealth Design LLC now owns 390 shares of the company’s stock worth $26,000 after buying an additional 264 shares in the last quarter. Total Investment Management Inc. bought a new stake in Corteva during the second quarter worth about $27,000. Curat Global LLC grew its position in Corteva by 93.7% during the second quarter. Curat Global LLC now owns 370 shares of the company’s stock valued at $28,000 after acquiring an additional 179 shares during the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new position in shares of Corteva during the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva Stock Performance

NYSE CTVA opened at $72.50 on Friday. Corteva, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $77.41. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.07 and a current ratio of 1.43. The business’s 50 day moving average price is $68.72 and its 200-day moving average price is $68.43. The company has a market cap of $48.99 billion, a P/E ratio of 45.89, a P/E/G ratio of 1.86 and a beta of 0.75.

Corteva (NYSE:CTVA) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same period in the prior year, the company posted $0.32 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Sell-side analysts predict that Corteva, Inc. will post 2.96 earnings per share for the current year.

Corteva Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be paid a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Monday, March 2nd. Corteva’s payout ratio is currently 45.57%.

Wall Street Analyst Weigh In

Several analysts have weighed in on CTVA shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $88.00 price objective on shares of Corteva in a research report on Thursday. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Corteva from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Corteva in a research note on Monday, December 29th. Rothschild & Co Redburn dropped their target price on shares of Corteva from $71.00 to $65.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th. Finally, Wells Fargo & Company raised their price objective on Corteva from $77.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.84.

Key Headlines Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: RBC raised its price target to $89 and kept an “outperform” rating, signaling sizable upside from current levels and supporting bullish investor views. RBC raises price target
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.45–$3.70 (above Street consensus ~3.23) and the company highlighted record free cash flow and a strong second half, which underpin longer‑term earnings visibility. Guidance and metrics Earnings highlights
• Neutral Sentiment: Analyst views are mixed across the sector, with some firms more cautious and others bullish — adding to day‑to‑day volatility as investors weigh differing valuations and demand outlooks. Conflicting analyst sentiments
• Neutral Sentiment: Full earnings materials and the call transcript are available; they show operational detail that investors will parse (product mix, regional timing) — useful for medium‑term positioning but containing both upside and downside signals. Earnings transcript
• Negative Sentiment: JPMorgan downgraded CTVA from “overweight” to “neutral,” citing limited valuation upside despite raising its target slightly to $77 — a headline catalyst for selling pressure. JPMorgan downgrade
• Negative Sentiment: Corteva missed Q4 revenue expectations as seasonal timing shifts and weaker crop protection/seed demand weighed, and the company reported a wider loss after hours — immediate negative for near‑term sentiment and the main driver of the intraday drop. Revenue miss article After-hours reaction

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.